|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2005-5-23
|
|
pubmed:abstractText |
In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC). Results for the parent study of IFL/BV versus IFL/placebo are reported elsewhere. Here, we describe efficacy and safety results for the third patient cohort in this trial, who received BV combined with FU/LV, and compare them with results for concurrently enrolled patients who received IFL.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3502-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15908660-Adult,
pubmed-meshheading:15908660-Aged,
pubmed-meshheading:15908660-Antibodies, Monoclonal,
pubmed-meshheading:15908660-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15908660-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15908660-Colorectal Neoplasms,
pubmed-meshheading:15908660-Dose-Response Relationship, Drug,
pubmed-meshheading:15908660-Drug Administration Schedule,
pubmed-meshheading:15908660-Female,
pubmed-meshheading:15908660-Fluorouracil,
pubmed-meshheading:15908660-Humans,
pubmed-meshheading:15908660-Leucovorin,
pubmed-meshheading:15908660-Male,
pubmed-meshheading:15908660-Maximum Tolerated Dose,
pubmed-meshheading:15908660-Middle Aged,
pubmed-meshheading:15908660-Neoplasm Invasiveness,
pubmed-meshheading:15908660-Neoplasm Metastasis,
pubmed-meshheading:15908660-Neoplasm Staging,
pubmed-meshheading:15908660-Probability,
pubmed-meshheading:15908660-Prognosis,
pubmed-meshheading:15908660-Risk Assessment,
pubmed-meshheading:15908660-Survival Analysis,
pubmed-meshheading:15908660-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology and Transplantation, Room 25132, Morris Building, Box 3052, Duke University Medical Center, Durham, NC 27710, USA. hurwi004@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
